Table 1.
Demographic and Baseline Characteristics (Intention-to-Treat)
| Characteristics | TPZ (n=175) | LPZ (n=175) |
|---|---|---|
| Age, yr | 54.71±11.24 | 53.19±10.88 |
| Sex | ||
| Male | 85 (48.57) | 83 (47.43) |
| Female | 90 (51.43) | 92 (52.57) |
| Height, cm | 164.03±9.32 | 163.31±8.56 |
| Weight, kg | 65.64±11.26 | 64.17±11.95 |
| Smoking | ||
| Yes | 26 (14.86) | 24 (13.71) |
| No | 149 (85.14) | 151 (86.29) |
| Alcohol drinking | ||
| Yes | 57 (32.57) | 76 (43.43) |
| No | 118 (67.43) | 99 (56.57) |
| Underlying gastric diseases | ||
| Peptic ulcer disease | 50 (28.57) | 50 (28.57) |
| Chronic atrophic gastritis | 125 (71.43) | 125 (71.43) |
| CYP2C19 genotype test* | ||
| Extensive/Intermediate metabolizer | 127 (88.81) | 129 (85.43) |
| Poor metabolizer | 16 (11.19) | 22 (14.57) |
| Clarithromycin susceptibility† | ||
| Susceptible or intermediate (MIC ≤0.5 μg/mL) | 27 (72.97) | 26 (66.67) |
| Resistant (MIC >0.5 μg/mL) | 10 (27.03) | 13 (33.33) |
| AMX susceptibility† | ||
| Susceptible or intermediate (MIC ≤0.125 μg/mL) | 29 (78.38) | 28 (71.79) |
| Resistant (MIC >0.125 μg/mL) | 8 (21.62) | 11 (28.21) |
Data are presented as mean±SD or number (%).
TPZ, tegoprazan-based triple therapy; LPZ, lansoprazole-based triple therapy; CYP, cytochrome P450; MIC, minimum inhibitory concentration; AMX, amoxicillin.
*Only the participants who consented to the genetic test were tested; †Gastric mucosa specimens were obtained from only 88 patients; among them, the MIC test was performed for the 76 patients in whose samples Helicobacter pylori culture was successful.